Logo

Turning Point's Repotrectinib Receives the US FDA's Breakthrough Therapy Designation for the Treatment of ROS1-Positive Metastatic Non-Small Cell Lung Cancer

Share this

Turning Point's Repotrectinib Receives the US FDA's Breakthrough Therapy Designation for the Treatment of ROS1-Positive Metastatic Non-Small Cell Lung Cancer

Shots:

  • The US FDA has been granted BTD for the treatment of patients with ROS1+ metastatic NSCLC who have not been treated with ROS1 TKI-naïve
  • The designation is based on P-I & P-II portion of TRIDENT-1 study of repotrectinib in TKI-naïve ROS1-positive NSCLC patients. The study is currently evaluating patients in multiple potentially registrational cohorts
  • The company plans to report updated P-II TRIDENT-1 study results in patients with TKI-naive ROS1-positive NSCLC at the World Conference on Lung Cancer on Jan 31- 2021

 ­ Ref: GlobeNewswire | Image: Biocom

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions